ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 847

Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension

Silvia Laura Bosello1, Giacomo De Luca1, Franca Forni2, Clara Di Mario3, Federico parisi1, Giovanni Canestrari1, Giorgia Berardi1, Manuela Rucco1, Francesca Gabrielli4, Leonarda Galiuto4, Francesco Loperfido4 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Department of Laboratory Medicine, Catholic University of the Sacred Heart, Rome, Italy, 3Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 4Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, heart disease and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represents one of the leading cause of death in these patients. Recently it has been reported the role of NT-proBNP and high sensitivity Troponin T (cTnT) in patients with SSc-related pulmonary arterial hypertension (PAH), but their prognostic role is lacking in primary cardiac involvement. The aim of our study was to define the role of cardiac troponin T (cTnT) and NT-proBNP to identify cardiac involvement in SSc.

Methods: High sensitivity cTnT and NT-proBNP were measured in 200 consecutive SSc patients and in matched healthy controls. Patients with renal failure and with PAH on right heart catheterization were excluded. Data regarding disease subtype and organ involvement were available and all SSc-related deaths were registered. Classical cardiovascular risk factors were also considered. A mean follow-up of 48.6±20.6 months was reached.

Results:

cTnT levels and NT-proBNP values were higher in scleroderma patients (cTnT: 0.03±0.06 ng/ml and NTproBNP: 507.3±1718.9 pg/ml) than in healthy controls (cTnT: 0.006±0.0004 ng/ml and NT-proBNP: 90.6 ± 70.9,  pg/ml,p<0.00001 for both comparisons).

cTnT levels were upper the normal limit in 65 SSc patients (32.5%), 72.6% complained cardiac symptoms, while 27.4% was completely asymptomatics. At multivariate analysis diffuse skin involvement (RR: 2.1 [1.2-4.4] and the presence of right bundle branch block (RBBB) on ECG (RR: 8.1 [1.4-45.5]) emerged as indipendent predictors of elevation of cTNT. NT-proBNP levels were above the cut-off limit of 125 ng/ml, recommended by the manufacturer, in 66 patients (33.3%), 72% of whom complained cardiac symptoms, while 28% was asymptomatic. Thirty-eight patients (19.0%) presented either an increase of cTnT either of NT-proBNP. At multivariate analysis diffuse skin involvement (RR: 2.3 [1.1-4.9]) and age (RR: 1.2 [1.03-1.09]) were indipendent predictors of elevation of NT-proBNP.

During the follow-up, 12 SSc-related death occurred; 8 of these were directly related to cardiac involvement (sudden cardiac death or heart failure).  Cumulative survival estimated by Kaplan-Mayer curve was worse in patients with increased baseline levels of cTnT (Χ2=10.2, p=0.001) and NT-proBNP (Χ2=11.1, p=0.001), but patients with increase of cTnT and NT-proBNP had the worst outcome (Χ2=13.5, p=0.003).  

Conclusion:

cTnT and NT-proBNP are useful markers to identify symptomatic and asymptomatic SSc patients with a subclinical heart disease and a bad cardiac outcome.


Disclosure: S. L. Bosello, None; G. De Luca, None; F. Forni, None; C. Di Mario, None; F. parisi, None; G. Canestrari, None; G. Berardi, None; M. Rucco, None; F. Gabrielli, None; L. Galiuto, None; F. Loperfido, None; G. Ferraccioli, None.

To cite this abstract in AMA style:

Bosello SL, De Luca G, Forni F, Di Mario C, parisi F, Canestrari G, Berardi G, Rucco M, Gabrielli F, Galiuto L, Loperfido F, Ferraccioli G. Troponin T and NT-Probnp Are Prognostic Cardiac Disease Biomarkers in Patients with Systemic Sclerosis without Pulmonary Arterial Hypertension [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/troponin-t-and-nt-probnp-are-prognostic-cardiac-disease-biomarkers-in-patients-with-systemic-sclerosis-without-pulmonary-arterial-hypertension/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/troponin-t-and-nt-probnp-are-prognostic-cardiac-disease-biomarkers-in-patients-with-systemic-sclerosis-without-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology